Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar.

inflammation myocardial infarction sacubitril tachycardia, ventricular valsartan

Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
26 Apr 2024
Historique:
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: aheadofprint

Résumé

Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its mechanistic data on myocardial scar after myocardial infarction (MI) are lacking. The objective of this work was to assess the effects of Sac/Val on inflammation, fibrosis, electrophysiological properties, and ventricular tachycardia inducibility in post-MI scar remodeling in swine. After MI, 22 pigs were randomized to receive β-blocker (BB; control, n=8) or BB+Sac/Val (Sac/Val, n=9). The systemic immune response was monitored. Cardiac magnetic resonance data were acquired at 2-day and 29-day post MI to assess ventricular remodeling. Programmed electrical stimulation and high-density mapping were performed at 30-day post MI to assess ventricular tachycardia inducibility. Myocardial samples were collected for histological analysis. Compared with BB, BB+Sac/Val reduced acute circulating leukocytes ( After MI, compared with BB, BB+Sac/Val was associated with reduced acute systemic inflammatory markers, reduced total scar and border zone mass on late gadolinium-enhanced magnetic resonance imaging, and lower ventricular tachycardia inducibility.

Sections du résumé

BACKGROUND UNASSIGNED
Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its mechanistic data on myocardial scar after myocardial infarction (MI) are lacking. The objective of this work was to assess the effects of Sac/Val on inflammation, fibrosis, electrophysiological properties, and ventricular tachycardia inducibility in post-MI scar remodeling in swine.
METHODS UNASSIGNED
After MI, 22 pigs were randomized to receive β-blocker (BB; control, n=8) or BB+Sac/Val (Sac/Val, n=9). The systemic immune response was monitored. Cardiac magnetic resonance data were acquired at 2-day and 29-day post MI to assess ventricular remodeling. Programmed electrical stimulation and high-density mapping were performed at 30-day post MI to assess ventricular tachycardia inducibility. Myocardial samples were collected for histological analysis.
RESULTS UNASSIGNED
Compared with BB, BB+Sac/Val reduced acute circulating leukocytes (
CONCLUSIONS UNASSIGNED
After MI, compared with BB, BB+Sac/Val was associated with reduced acute systemic inflammatory markers, reduced total scar and border zone mass on late gadolinium-enhanced magnetic resonance imaging, and lower ventricular tachycardia inducibility.

Identifiants

DOI: 10.1161/CIRCEP.123.012517 PMID: 38666379
pubmed: 38666379
doi: 10.1161/CIRCEP.123.012517
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012517

Auteurs

Daina Martínez-Falguera (D)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).
Faculty of Medicine, University of Barcelona, Spain (D.M.-F.).
ORCID: 0000-0002-9439-0542

Júlia Aranyó (J)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
Department of Medicine, Autonomous University of Barcelona, Spain (J.A., A.B.-G.).
ORCID: 0000-0002-4059-6297

Albert Teis (A)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
ORCID: 0000-0002-4820-0736

Gemma Ferrer-Curriu (G)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).

Marta Monguió-Tortajada (M)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).
ORCID: 0000-0003-2125-0810

Edgar Fadeuilhe (E)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
ORCID: 0000-0003-0079-224X

Oriol Rodríguez-Leor (O)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain (O.R.-L., S.R., R.V., A.B-G., F.B., C.G.-M.).
ORCID: 0000-0003-2657-5657

Idoia Díaz-Güemes (I)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).

Santiago Roura (S)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).
Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain (O.R.-L., S.R., R.V., A.B-G., F.B., C.G.-M.).
Faculty of Medicine, University of Vic-Central University of Catalonia, Barcelona, Spain (S.R.).

Roger Villuendas (R)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain (O.R.-L., S.R., R.V., A.B-G., F.B., C.G.-M.).
ORCID: 0000-0001-9110-905X

Axel Sarrias (A)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
ORCID: 0000-0001-6712-3097

Victor Bazan (V)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
ORCID: 0000-0001-8072-7434

Victoria Delgado (V)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
ORCID: 0000-0002-9841-2737

Antoni Bayes-Genis (A)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).
Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
Department of Medicine, Autonomous University of Barcelona, Spain (J.A., A.B.-G.).
CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain (O.R.-L., S.R., R.V., A.B-G., F.B., C.G.-M.).
ORCID: 0000-0002-3044-197X

Felipe Bisbal (F)

Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain (O.R.-L., S.R., R.V., A.B-G., F.B., C.G.-M.).
ORCID: 0000-0002-4843-7063

Carolina Gálvez-Montón (C)

ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).
Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Barcelona, Spain (J.A., A.T., E.F., O.R.-L., S.R., R.V., A.S., V.B., V.D., A.B.-G., F.B., C.G.-M.).
CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain (O.R.-L., S.R., R.V., A.B-G., F.B., C.G.-M.).
ORCID: 0000-0003-2254-9371

Classifications MeSH